A large European clinical trial found that sulthiame, an existing epilepsy medication, reduced breathing interruptions during sleep by up to 47% in patients with moderate to severe obstructive sleep apnea, raising hopes for a pharmaceutical alternative to CPAP therapy.
Continue Reading →Pharmaceutical company Apnimed plans to file for FDA approval of AD109 in early 2026 after the drug met its primary endpoint in a second Phase 3 trial, potentially offering relief to patients who struggle with CPAP therapy.
UC Davis Medical Center became the first hospital in Northern California to implant the Genio system, an FDA-approved device that stimulates nerves to keep airways open during sleep without requiring an internal battery.
SleepRes received FDA 510(k) clearance for its Kricket PAP device, which uses adaptive pressure technology to synchronize with natural breathing patterns and potentially improve patient comfort.